| 商品名称 | Sutent |
|---|---|
| 适用类别 | Human |
| 治疗领域 | Gastrointestinal Stromal Tumors;Carcinoma, Renal Cell;Neuroendocrine Tumors |
| 通用名/非专利名称 | sunitinib |
| 活性成分 | sunitinib |
| 产品号 | EMEA/H/C/000687 |
| 患者安全信息 | No |
| 许可状态 | Authorised |
| ATC编码 | L01EX01 |
| 是否额外监管 | No |
| 是否仿制药或hybrid药物 | No |
| 是否生物类似药 | No |
| 是否附条件批准 | No |
| 是否特殊情形 | No |
| 是否加速审评 | No |
| 是否罕用药 | No |
| 上市许可日期 | 2006/07/19 |
| 上市许可开发者/申请人/持有人 | Pfizer Limited |
| 人用药物治疗学分组 | Antineoplastic agents |
| 兽用药物治疗学分组 | |
| 欧盟委员会决定日期 | 2025/03/10 |
| 修订号 | 41 |
| 治疗适应症 | Gastrointestinal stromal tumour (GIST) Sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. Metastatic renal cell carcinoma (MRCC) Sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults. Pancreatic neuroendocrine tumours (pNET) Sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. Experience with Sutent as first-line treatment is limited (see section 5.1). |
| 适用物种 | |
| 兽用药物ATC编码 | |
| 首次发布日期 | 2018/02/22 |
| 最后更新日期 | 2025/03/10 |
| 产品说明书 | https://www.ema.europa.eu/en/documents/product-information/sutent-epar-product-information_en.pdf |
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/human/EPAR/sutent |